Impaired Pancreatic Polypeptide Responses to Insulin-Induced Hypoglycemia in Diabetic Autonomic Neuropathy*

Authors:

Abstract
Human pancreatic polypeptide (hPP) responses to insulin-induced hypoglycemia have been measured in normal subjects (n = 5), in age- and weight-matched diabetics with clinical evidence of autonomic neuropathy (AN) (n = 5), and in diabetics without clinical evidence of AN (n =5). Mean basal hPP concentrations were similar in the diabetics with AN (165 ± 40 pg/ml) and in the diabetics without AN (170 ±51 pg/ml) and were not significantly different from that in normal controls (139 ± 42 pg/ml). The hPP response to insulin-induced hypoglycemia in the diabetics without AN (plasma glucose nadir, 69 ±23.1 mg/dl) was comparable with that in normal controls (glucose nadir, 30 ± 4.3 mg/dl), but in diabetics with AN (glucose nadir, 62.4 ± 11.9 mg/dl) there was an impaired rise in hPP concentrations (654 ± 250 pg/ml) compared with either normal controls (3020 ±397 pg/ml) or diabetics without AN (3003 ±793 pg/ml). Twelve-hour insulin infusion lowered fasting plasma glucose to normal in both groups of diabetics. Acutely administered insulin loweredplasma glucose to 31 ± 6.3 mg/dl andb increased the mean maximum hPP concentration to 1248 ±356 pg/ml in diabetics with AN, but the response was still impaired compared with controls and diabetics without AN (3178 ± 460 pg/ml) in whom the mean nadir in plasma glucose achieved was 23 ± 3.5 mg/dl. Although an impaired hPP response to hypoglycemia was uniformly found in all diabetics with AN, there was no correlation between the impaired hPP responses and other individual clinical indices of autonomic nervous dysfunction in the small number of people studied.